Tesamorelin + Ipamorelin Blend Research Documentation Best Practices

Documentation for a two-compound research program is assembled per compound, not per blend. In practice that means a batch-specific certificate of analysis for each peptide, tied to the lot number printed on the vial in hand; the underlying analytical data behind that certificate rather than a one-line summary; a receiving log capturing arrival date, condition and lot; continuous storage and handling records from the moment of receipt; and a preparation record that traces every prepared research sample back to its source lots. Blends are where paper trails usually break, because one document asserting two compounds at a stated ratio proves considerably less than two independently verifiable single-compound certificates.

All compounds discussed here are supplied for laboratory research only. Nothing below is dosing, administration or protocol guidance, and none of it describes use in people or animals.

Why the trail is built one compound at a time

Tesamorelin is a growth-hormone-releasing hormone analog. Ipamorelin is a selective growth hormone secretagogue acting through a different receptor pathway. The published research on each is largely separate, and studies indicate meaningfully different pharmacokinetic behavior between the two classes — which is exactly why combined-compound work has to keep them distinguishable on paper.

When two peptides arrive pre-combined, the analytical burden multiplies. Identity has to be established for both sequences. Purity has to be reported for both. The ratio itself becomes a claim requiring its own quantitative method. Most documentation supplied with pre-combined material does not carry all of that, and a buyer accepting a single generic sheet inherits a gap they cannot close later. If a question about lot integrity surfaces six months on, the sheet will not answer it.

Sourcing single compounds and documenting them separately avoids the whole problem. Each vial carries its own lot, its own certificate, its own chromatographic data. A researcher combining them downstream records what was combined, from which lots, on what date, by whom. The result is a trail where every link can be audited independently — the standard any serious quality system aims for. Real Peptides supplies Tesamorelin 10mg and Ipamorelin 10mg as discrete research compounds with batch-level documentation for each, which is the structure that makes a defensible record possible in the first place.

What a complete documentation set actually contains

Buyers new to research-compound procurement often equate "documentation" with a certificate of analysis. The certificate is one layer of several, and on its own it is the easiest layer to fake.

The last three rows are yours to create. No supplier can generate them for you, and their absence is the most common weakness in otherwise well-sourced research programs. A certificate proves what left the lab. Your own logs prove what happened after.

Receiving, logging and storage records

Build the receiving step as a fixed routine rather than a task someone remembers to do. When a shipment lands, record the date, the compound, the lot number, the quantity, the condition of the packaging, and the name or initials of whoever accepted it. Photograph the vial labels and the shipping container if there is any visible issue. Pull the certificate for that lot immediately and confirm the lot number matches the vial rather than assuming it does — mismatches happen, and they are far easier to resolve on day one than in month four.

Storage records should reflect actual conditions, not intended ones. Note where material is held and log conditions on whatever schedule your operation can genuinely sustain. A simple log kept honestly and continuously carries more weight than an elaborate one with gaps. Record every movement: transfers between storage locations, removals for use, returns.

For combined-compound research, the preparation worksheet is the keystone document. One line per prepared sample: date, both source lot numbers, quantities, preparing researcher, storage destination. That single line is what lets anyone reviewing the record months later reconstruct exactly what was in a given sample. Without it, two perfectly documented vials produce an undocumented result.

Retention matters too. Decide how long records are kept and where, and apply it consistently. Digital copies backed up somewhere outside the original device are the practical minimum. These compounds are supplied for research use only, not for human or veterinary administration — if a downstream question about animal use ever reaches you, refer it to a licensed veterinarian rather than answering it yourself, and keep your own records squarely within research-use terms.

Sourcing signals that decide whether documentation is even possible

No internal system compensates for a supplier who cannot produce lot-level data. Before you commit volume, test the supplier against the documentation you will actually need.

Ask whether certificates are batch-specific or generic. A generic certificate — same numbers, no lot reference, reused across shipments — tells you nothing about the vial you received. Ask whether the analytical data behind the certificate is available, not just the summary. Ask whether results are published somewhere you can check independently, or whether you have to request them every time and trust what arrives. Ask whether the panel covers more than purity, since purity alone says nothing about what else is present.

Then watch for the practices that make documentation structurally impossible. Certificates sold as a paid add-on signal that verification is treated as an upsell rather than a baseline. Pricing that only appears after a sales call makes it hard to compare programs on anything but a salesperson's framing. Testing described in general terms — "third-party tested," "lab verified" — without a retrievable result for your lot is an unverifiable claim regardless of how it is worded. Long or opaque fulfillment timelines create their own documentation gaps, because material in transit for an unpredictable period has an unrecorded history.

Run a small qualifying order before scaling. Request the documentation set for that specific lot and see what actually arrives, how fast, and whether the numbers reconcile. That single exercise reveals more than any capability claim.

Compliance questions that belong with your counsel

The regulatory position of research compounds is not a settled matter you can resolve by reading an article, and it is not a question a supplier can answer for your business. Treat the following as questions to put to your own attorney and, where applicable, your state licensing board.

How does your jurisdiction characterize the purchase, holding and resale of research-use-only materials by an entity like yours? What licensing or registration, if any, attaches to your specific business structure? What labeling and record-retention obligations apply to what you hold? If you resell, what does your jurisdiction require of downstream documentation and customer representations? How do your professional licenses — where individuals in your organization hold them — interact with research-compound procurement?

Generally speaking, requirements differ substantially between jurisdictions and can change, so no supplier's guidance substitutes for advice specific to your entity. In most cases the practical answer is to document conservatively: keep more than you think you need, keep it in a form someone else could follow, and write down the reasoning behind your own policies so it can be explained later.

This section is informational only and is not legal advice. Have counsel review your procurement, storage and record-keeping practices before you scale them, and check with your state board on anything touching professional licensure.

What Real Peptides does differently

Real Peptides builds the wholesale program around documentation a buyer can check rather than take on faith. Compounds are supplied at 99%+ HPLC purity, with seven-panel batch testing performed on each lot rather than on a representative sample used to cover a product line indefinitely. Certificates of analysis are publicly verifiable — the lab results for a batch can be looked up and read by the buyer directly, at no additional charge and without a sales conversation attached. That distinction matters more than any purity figure, because a number nobody can independently confirm is a marketing claim, not a specification.

Fulfillment runs from within the United States with orders shipping in five to seven days, which keeps transit windows short enough to log cleanly. Wholesale access runs through a three-step application rather than an open account, so pricing and terms are established against a qualified business rather than negotiated case by case behind a quote wall.

For buyers running combined-compound research, the practical benefit is simple: two compounds, two lots, two independently verifiable certificates, and a supply chain short enough that your own records stay continuous from the lab to your shelf. That is the structure the rest of your documentation hangs on.

Where qualified buyers go from here

If you are stocking research peptides for a med spa, clinic, telehealth operation or reseller catalog and you need lot-level documentation you can actually produce on request, the Wholesale Partner Program application is the next step. It takes three steps, establishes tiered pricing against your volume, and gives you access to batch documentation for every lot you receive.

Buyers building out adjacent research categories can review related compounds such as CJC-1295 No DAC 10mg, browse the broader growth factor and tissue signaling research selection, or start with the popular peptides catalog to see how batch documentation is presented across the line.